Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > 2 drugs target common genetic heart risk factor lipoprotein(a)
Health and Wellness

2 drugs target common genetic heart risk factor lipoprotein(a)

Last updated: November 19, 2024 2:05 am
Share
2 drugs target common genetic heart risk factor lipoprotein(a)
SHARE

Lipoprotein(a) is a lesser-known risk factor for cardiovascular disease that often goes undetected during routine physical exams. Similar to LDL, or “bad” cholesterol, high levels of lipoprotein(a) can lead to the formation of plaque in the arteries, increasing the risk of heart attacks, strokes, and aortic stenosis.

Unlike cholesterol, lipoprotein(a) is not influenced by statins or lifestyle changes such as diet and exercise. Instead, its levels are primarily determined by genetics, making it challenging to manage for the estimated 1 in 5 individuals with elevated levels. In the United States alone, about 64 million people are at risk, with a staggering 1.4 billion people worldwide facing potential complications due to high lipoprotein(a) levels.

Recently, at the American Heart Association’s scientific sessions, researchers presented Phase 2 data on two promising treatments for elevated lipoprotein(a). The first is an oral drug called muvalaplin, which showed positive results in reducing lipoprotein(a) levels. The second treatment is an RNA-silencing injection known as zerlasiran, which also demonstrated efficacy in managing elevated lipoprotein(a) levels. Both studies were published in JAMA and involved leading experts in the field, including Steven Nissen from the Cleveland Clinic and Stephen Nicholls from Monash University.

These findings are significant as they offer hope for individuals with high lipoprotein(a) levels who have few treatment options available. The development of targeted therapies like muvalaplin and zerlasiran could potentially reduce the risk of cardiovascular events and improve outcomes for millions of people at risk of complications associated with elevated lipoprotein(a).

Overall, the research presented at the American Heart Association’s scientific sessions highlights the importance of addressing lipoprotein(a) as a significant risk factor for cardiovascular disease and the potential for innovative treatments to make a difference in managing this condition. The promising results of these studies provide a glimpse of hope for individuals with high lipoprotein(a) levels and pave the way for future advancements in the field of cardiovascular medicine.

See also  What Baby KJ means for future of CRISPR gene editing industry
TAGGED:CommonDrugsfactorgeneticheartlipoproteinaRiskTarget
Share This Article
Twitter Email Copy Link Print
Previous Article WNBA mock draft: After Wings win lottery for Paige Bueckers, who goes next? WNBA mock draft: After Wings win lottery for Paige Bueckers, who goes next?
Next Article WHAT A SHAME: Biased Associated Press Announces Staff Layoffs and Buyouts | WHAT A SHAME: Biased Associated Press Announces Staff Layoffs and Buyouts |
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Microscopic plant stones can cause permanent damage to tooth enamel

Tooth enamel, the hardest substance in the human body, may be at risk of gradual…

July 7, 2025

Meghan Markle Is Feared to Have Left Herself ‘Wide Open’ to Attacks

Meghan Markle Leaves Prince Harry's Invictus Games to Avoid PR Disaster The Duchess of Sussex,…

March 20, 2025

Classic Earth911 Podcast: How To Talk to the Other Side With Author Kevin Wilhelm

In a recent Earth911 podcast, author and sustainability consultant Kevin Wilhelm discussed his book "How…

March 5, 2025

Paramount, Swinging to Q1 Profit, Says Skydance Deal to Close by June

Paramount Global Reports Profit in First Quarter Amid Skydance Acquisition Deal Paramount Global, currently in…

May 8, 2025

This is The Best Budget Pixel Deal This Black Friday

Black Friday has brought some incredible discounts, including a fantastic deal on Google's impressive phone,…

November 30, 2024

You Might Also Like

Cigna Profits Hit Nearly  Billion Despite Rising Costs
Health and Wellness

Cigna Profits Hit Nearly $2 Billion Despite Rising Costs

October 30, 2025
For cardiac health, exercise benefits women more than men
Health and Wellness

For cardiac health, exercise benefits women more than men

October 30, 2025
Hydrogen gas found to play key role in supporting gut health
Health and Wellness

Hydrogen gas found to play key role in supporting gut health

October 30, 2025
Alignment Healthcare Reports Second Profitable Quarter By Taming Costs
Health and Wellness

Alignment Healthcare Reports Second Profitable Quarter By Taming Costs

October 30, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?